Everything Life Sciences Companies Need to Know to Navigate the COVID-19 Pandemic
Join Mintz and ML Strategies for a webinar on a spectrum of legal issues companies in the life sciences industry are facing during this complicated period. The program will cover issues of:
Employment Law
-
Defining “essential” businesses
-
What to do if an employee in your essential business chooses not to work
-
How/what to communicate when an employee tests positive
-
Communications regarding a positive test
FDA
-
Emergency use authorizations (EUAs) and enforcement discretion policies
-
Program setup for developers of potential COVID-19 therapeutics
-
Actions to help alleviate regulatory burdens on existing product sponsors in the life sciences industry
Clinical Trials
-
Regulatory authority accommodations for ongoing clinical trials that may be affected by COVID-19 and regional restrictions
-
Key considerations for sponsors and sites regarding ongoing and planned clinical trials
M&A
-
State of the M&A deal market
-
Impacts on deal processes and associated timeline
-
Allocating pandemic risk (MAC clauses come into focus)
Capital Markets
-
State of the public capital markets
-
Recent SEC developments related to COVID-19
-
Impacts on financing options for life sciences companies
Federal Legislation
-
Accessing funds for businesses creating COVID-19 diagnostics, therapeutics or vaccines
-
Financial assistance for businesses provided by CARES Act and other legislation
Moderator
Joshua D. Fox |
Speakers
|
Dianne Bourque |
Joanne S. Hawana |
![]() Aaron L. Josephson |
![]() Marc D. Mantell |
![]() H. Andrew Matzkin |
![]() John T. Rudy |
![]() Benjamin M. Zegarelli |